
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Mesa Laboratories Inc (MLAB)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MLAB (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $88.5
1 Year Target Price $88.5
2 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.1% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 373.49M USD | Price to earnings Ratio - | 1Y Target Price 88.5 |
Price to earnings Ratio - | 1Y Target Price 88.5 | ||
Volume (30-day avg) 4 | Beta 0.83 | 52 Weeks Range 55.45 - 154.70 | Updated Date 08/15/2025 |
52 Weeks Range 55.45 - 154.70 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 0.92% | Basic EPS (TTM) -0.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When Before Market | Estimate 2.38 | Actual 1.8811 |
Profitability
Profit Margin -0.26% | Operating Margin (TTM) 5.15% |
Management Effectiveness
Return on Assets (TTM) 2.04% | Return on Equity (TTM) -0.38% |
Valuation
Trailing PE - | Forward PE 35.21 | Enterprise Value 549807712 | Price to Sales(TTM) 1.54 |
Enterprise Value 549807712 | Price to Sales(TTM) 1.54 | ||
Enterprise Value to Revenue 2.27 | Enterprise Value to EBITDA 12.14 | Shares Outstanding 5501450 | Shares Floating 5344443 |
Shares Outstanding 5501450 | Shares Floating 5344443 | ||
Percent Insiders 5.12 | Percent Institutions 95.7 |
Upturn AI SWOT
Mesa Laboratories Inc

Company Overview
History and Background
Mesa Laboratories, Inc. was founded in 1982. It has evolved from a focus on quality control products for healthcare to a broader range of instruments, consumables, and services for life sciences, healthcare, and industrial applications. Mesa Labs has grown through organic expansion and strategic acquisitions.
Core Business Areas
- Sterilization and Disinfection Control: Provides biological indicators, chemical indicators, and process challenge devices used to monitor sterilization and disinfection processes in healthcare and industrial settings.
- Biopharmaceutical Development: Offers contract manufacturing and analytical testing services for biopharmaceutical companies.
- Instruments: Designs and manufactures instruments used for environmental monitoring, calibration, and data logging across various industries.
Leadership and Structure
The leadership team includes the CEO, CFO, and other key executives responsible for different business segments. The company has a board of directors overseeing strategy and governance. Typically follows a functional organizational structure with departments like R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- Biological Indicators (BIs): Used to validate sterilization processes. Market share information is not readily and publicly available. Competitors include STERIS (STE), 3M (MMM) and Getinge AB (GETI-B.ST).
- Data Loggers: Used for continuous monitoring of temperature, humidity, and pressure. Market share information is not readily and publicly available. Competitors include Vaisala, Dickson and MadgeTech.
- Contract Sterility Testing Services: Services provided to pharmaceutical companies for drug product testing. Market share information is not readily and publicly available. Competitors include SGS S.A. (SGSO.SW), Charles River Laboratories (CRL) and Eurofins Scientific (ERF.PA).
Market Dynamics
Industry Overview
The industry includes sterilization and disinfection control, contract manufacturing and analytical testing, and environmental monitoring. Growth is driven by increasing regulatory requirements, healthcare spending, and demand for biopharmaceuticals.
Positioning
Mesa Laboratories positions itself as a provider of high-quality, reliable solutions for critical quality control and testing needs. Its competitive advantages include its strong brand reputation, technical expertise, and focus on niche markets.
Total Addressable Market (TAM)
The TAM across its segments is estimated to be several billion USD annually. Mesa Labs is positioned to capture a portion of this market through its specialized offerings.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Technical expertise
- Focus on niche markets
- Recurring revenue streams
- High regulatory barriers to entry
Weaknesses
- Limited scale compared to larger competitors
- Dependence on specific industries
- Potential for technological obsolescence
- Relatively high valuation metrics
Opportunities
- Expansion into new geographic markets
- Development of new products and services
- Acquisitions of complementary businesses
- Increased outsourcing of biopharmaceutical services
- Growing regulatory requirements
Threats
- Intense competition
- Economic downturns
- Changes in regulatory requirements
- Technological advancements by competitors
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- STE
- MMM
- CRL
Competitive Landscape
Mesa Laboratories competes with larger companies in some segments, but it has a competitive advantage in niche markets due to its specialized expertise and strong brand reputation.
Major Acquisitions
Apex Pro LLC
- Year: 2021
- Acquisition Price (USD millions): 81
- Strategic Rationale: Expanded presence in the medical device industry and expanded access to customers.
Growth Trajectory and Initiatives
Historical Growth: Mesa Laboratories has historically grown through a combination of organic growth and strategic acquisitions.
Future Projections: Future growth projections depend on continued demand for its products and services, as well as successful execution of its acquisition strategy.
Recent Initiatives: Recent strategic initiatives may include acquisitions of companies in complementary markets or investments in new technologies.
Summary
Mesa Laboratories is a strong company with a focus on niche markets and high regulatory barriers. The company has a good brand reputation and is growing, but it has limited scale compared to larger competitors and a relatively high valuation. Going forward, MLAB needs to continue investing in innovation to stave off competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mesa Laboratories Inc
Exchange NASDAQ | Headquaters Lakewood, CO, United States | ||
IPO Launch date 1995-01-25 | CEO, President & Director Mr. Gary M. Owens | ||
Sector Technology | Industry Scientific & Technical Instruments | Full time employees 730 | Website https://www.mesalabs.com |
Full time employees 730 | Website https://www.mesalabs.com |
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.